TABLE 2.
Cox proportional hazard model of overall survival and progression‐free survival with circulating tumor DNA (ctDNA) mutations (N = 95).
| N | Overall survival | Progression‐free survival | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Event | Univariable | Adjusted stage | Event | Univariable | Adjusted stage | ||||||
| HR (95% CI) | p‐Value | HR (95% CI) | p‐Value | HR (95% CI) | p‐Value | HR (95% CI) | p‐Value | ||||
| Status | |||||||||||
| Resectable | 43 | 32 | 1 (ref) | 1 (ref) | 34 | 1 (ref) | 1 (ref) | ||||
| Locally advanced/metastatic | 52 | 51 | 4.790 (2.950–7.776) | <0.0001 | 3.312 (1.901–5.771) | <0.0001 | 52 | 4.392 (2.663–7.244) | <0.0001 | 3.330 (1.869–5.933) | <0.0001 |
| Sex | |||||||||||
| Female | 43 | 38 | 1 (ref) | 39 | 1 (ref) | ||||||
| Male | 52 | 45 | 0.945 (0.613–1.456) | 0.7964 | 47 | 0.999 (0.653–1.528) | 0.9953 | ||||
| Tumor location | |||||||||||
| Head or neck or uncinate process | 49 | 45 | 1 (ref) | 46 | 1 (ref) | ||||||
| Body or tail | 46 | 38 | 0.548 (0.354–0.849) | 0.0071 | 40 | 0.657 (0.428–1.007) | 0.0536 | ||||
| Age | 95 | 83 | 1.005 (0.979–1.032) | 0.7033 | 86 | 0.995 (0.969–1.022) | 0.7259 | ||||
| ECOG | |||||||||||
| 0 | 61 | 53 | 1 (ref) | 55 | 1 (ref) | ||||||
| 1, 2, 3 | 34 | 30 | 1.341 (0.854–2.104) | 0.2023 | 31 | 1.382 (0.887–2.153) | 0.1524 | ||||
| CEA Baseline | |||||||||||
| Low: CEA ≤ 5 | 43 | 33 | 1 (ref) | 35 | 1 (ref) | ||||||
| High: CEA > 5 | 49 | 47 | 2.363 (1.503–3.716) | 0.0002 | 48 | 2.084 (1.336–3.252) | 0.0012 | ||||
| CA19‐9 Baseline | |||||||||||
| Low: CA19‐9 ≤ 37 | 22 | 18 | 1 (ref) | 19 | 1 (ref) | ||||||
| High: CA19‐9 > 37 | 61 | 55 | 1.495 (0.875–2.554) | 0.1414 | 57 | 1.285 (0.764–2.163) | 0.3446 | ||||
| ctDNA Detection | |||||||||||
| Nondetected | 57 | 46 | 1 (ref) | 1 (ref) | 49 | 1 (ref) | 1 (ref) | ||||
| G12D/G12V/G12R/G12C Detected | 38 | 37 | 4.661 (2.900–7.493) | <0.0001 | 2.640 (1.545–4.510) | 0.0004 | 37 | 3.294 (2.095–5.179) | <0.0001 | 1.768 (1.048–2.981) | 0.0326 |